HIMSS: Thomson Reuters introduces Pharmacy Intervention, meaningful use strategies
ATLANTA – Technology company Thomson Reuters showcased an array of products focusing on the upcoming meaningful use requirements and real-time interoperability, including its latest Pharmacy Intervention application, at HIMSS10 this week.
The New York-based company introduced Pharmacy Intervention, a part of the Clinical Xpert suite of clinical workflow software which compares clinical profiles with data pulled from different hospital IT systems to automatically identify patients who are at-risk of an adverse drug event, such as someone who is on a potentially lethal combination or dosage of medications.
Pharmacists can access patient information from a web portal or mobile device and document their intervention directly at point of care, according to the company. Each intervention is attached directly to the patient record and can be viewed by all relevant care team members at any time. The application uses a forms-capture technology and tracks intervention to assess progress, according to Dave Mountain, director of marketing for healthcare and science at Thomson Reuters.
Pre-built profiles based on Micromedex reference information cover the following categories: antimicrobial monitoring, anticoagulation monitoring, glycemic monitoring, intravenous-to-oral conversion, narrow therapeutic indexing and patient safety.
Also highlighted this year was Micromedex 2.0, a search function that aggregates data and finds results on drugs, diseases, acute care and alternative medicines. According to the company, the latest version of Micromedex recognizes words that initiative assistance to help clinicians construct a query.
In addition, Micromedex will offer related content physicians may want to search based on the word choice. Micromedex’s application can also be pushed to a smartphone, said Mountain.
Thomson Reuters plans to certify four applications to meet specific meaningful use Stage 11 criteria. According to the company, they include:
CareDiscovery Quality Measures: The company plans to add a meaningful use quality reporting module that will be certified to support Criteria 11 (report hospital quality measures to CMS or the states);
Clinical Xpert CareFocus: Will be certified to support Criteria 10 (generate lists of patients by specific conditions to use for quality improvement, reduction of disparities, research and outreach) and Criteria 12 (implement five clinical decision support rules relevant to high clinical priority, including for diagnostic test ordering, along with the ability to track compliance with those rules);
Clincal Xpert Navigator: Will be certified to support Criteria 3 (maintain an up-to-date problem list of current and active diagnoses based on ICD-9-CM or SNOMED CT) and Criteria 4 (maintain active medication list); and
Micromedex CareNotes: Will be certified to meet Criteria 16 (provide patients with an electronic copy of their discharge instructions and procedures at time of discharge, upon request).
“If you look at what CMIOs are being expected to do and look at the 2015 meaningful use requirements, it’s all about measurable performance improvements,” said Jerome A. Osheroff, MD, chief infomtaion officer at Thomson Reuters. “CMIOs are increasingly working in collaboration, trying to help drive performance improvement.”
The New York-based company introduced Pharmacy Intervention, a part of the Clinical Xpert suite of clinical workflow software which compares clinical profiles with data pulled from different hospital IT systems to automatically identify patients who are at-risk of an adverse drug event, such as someone who is on a potentially lethal combination or dosage of medications.
Pharmacists can access patient information from a web portal or mobile device and document their intervention directly at point of care, according to the company. Each intervention is attached directly to the patient record and can be viewed by all relevant care team members at any time. The application uses a forms-capture technology and tracks intervention to assess progress, according to Dave Mountain, director of marketing for healthcare and science at Thomson Reuters.
Pre-built profiles based on Micromedex reference information cover the following categories: antimicrobial monitoring, anticoagulation monitoring, glycemic monitoring, intravenous-to-oral conversion, narrow therapeutic indexing and patient safety.
Also highlighted this year was Micromedex 2.0, a search function that aggregates data and finds results on drugs, diseases, acute care and alternative medicines. According to the company, the latest version of Micromedex recognizes words that initiative assistance to help clinicians construct a query.
In addition, Micromedex will offer related content physicians may want to search based on the word choice. Micromedex’s application can also be pushed to a smartphone, said Mountain.
Thomson Reuters plans to certify four applications to meet specific meaningful use Stage 11 criteria. According to the company, they include:
CareDiscovery Quality Measures: The company plans to add a meaningful use quality reporting module that will be certified to support Criteria 11 (report hospital quality measures to CMS or the states);
Clinical Xpert CareFocus: Will be certified to support Criteria 10 (generate lists of patients by specific conditions to use for quality improvement, reduction of disparities, research and outreach) and Criteria 12 (implement five clinical decision support rules relevant to high clinical priority, including for diagnostic test ordering, along with the ability to track compliance with those rules);
Clincal Xpert Navigator: Will be certified to support Criteria 3 (maintain an up-to-date problem list of current and active diagnoses based on ICD-9-CM or SNOMED CT) and Criteria 4 (maintain active medication list); and
Micromedex CareNotes: Will be certified to meet Criteria 16 (provide patients with an electronic copy of their discharge instructions and procedures at time of discharge, upon request).
“If you look at what CMIOs are being expected to do and look at the 2015 meaningful use requirements, it’s all about measurable performance improvements,” said Jerome A. Osheroff, MD, chief infomtaion officer at Thomson Reuters. “CMIOs are increasingly working in collaboration, trying to help drive performance improvement.”